Maximizing CAR-T cell yields: scalable solutions with perfusion and stirred-tank bioreactors

The primary drivers impacting cell and gene therapy (CGT) time-to-market and COGs include productivity, enabling process control, and ensuring the quality of the final cell product. Achieving these goals requires a functional supply chain and the ability to seamlessly scale-up. This article will discuss the collaborative study between Satorius and University College London, exploring process intensification strategies in stirred-tank bioreactors for CAR-T manufacturing.

Please enter your email to access content Read now